Nano X Imaging vs Abbott Laboratories: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Nano X Imaging Ltd (NNOX)

Q3 20267 Jul – 12 Sep 2026

▼3

Nano-X: Q2 revenue up 37% but going-concern doubt and lawsuits weigh

Securities class action lawsuits pile up Multiple law firms filed class actions alleging Nano-X overstated efficiency and demand, hid rising costs and cash burn, and misled investors. Legal costs, potential damages, and reputational damage weigh on the stock, though the suits are still pending.
This is a major new legal overhang that directly pressures NNOX shares.
Going-concern doubt after Q2 report Nano-X ended Q2 with $31.4 million cash, down from $60 million, and management warned of substantial doubt about continuing as a going concern. A $40.7 million impairment and $55.5 million net loss deepen fears of a cash crunch, pushing the stock down.
Going-concern doubt is a severe new risk that directly threatens the company's survival and stock price.
Revenue growth but slow commercialization Q2 revenue rose 37% to $4.2 million, with teleradiology up 14% and AI/software adding $1 million. The first Nanox Imaging Network site began collecting insurance payments, but management admitted commercialization is slower than expected, tempering the positive growth.
This shows the underlying business is growing but not fast enough to offset cash burn, a key tension for the stock.
Restructuring and manufacturing shift Nano-X is idling its South Korean chip fabrication, cutting that workforce by 67% and Israeli headcount by 15%, and shifting to third-party manufacturing. The plan saves only $2 million a year from 2027, raising doubts about its impact.
The restructuring is a direct response to the cash crisis and signals deeper operational problems.

August 20267 Jul – 12 Sep 2026

▼3

Nano-X: Q2 revenue up 37% but going-concern doubt and lawsuits weigh

Securities class action lawsuits pile up Multiple law firms filed class actions alleging Nano-X overstated efficiency and demand, hid rising costs and cash burn, and misled investors. Legal costs, potential damages, and reputational damage weigh on the stock, though the suits are still pending.
This is a major new legal overhang that directly pressures NNOX shares.
Going-concern doubt after Q2 report Nano-X ended Q2 with $31.4 million cash, down from $60 million, and management warned of substantial doubt about continuing as a going concern. A $40.7 million impairment and $55.5 million net loss deepen fears of a cash crunch, pushing the stock down.
Going-concern doubt is a severe new risk that directly threatens the company's survival and stock price.
Revenue growth but slow commercialization Q2 revenue rose 37% to $4.2 million, with teleradiology up 14% and AI/software adding $1 million. The first Nanox Imaging Network site began collecting insurance payments, but management admitted commercialization is slower than expected, tempering the positive growth.
This shows the underlying business is growing but not fast enough to offset cash burn, a key tension for the stock.
Restructuring and manufacturing shift Nano-X is idling its South Korean chip fabrication, cutting that workforce by 67% and Israeli headcount by 15%, and shifting to third-party manufacturing. The plan saves only $2 million a year from 2027, raising doubts about its impact.
The restructuring is a direct response to the cash crisis and signals deeper operational problems.

Latest7 Jul – 12 Sep 2026

▼3

Nano-X: Q2 revenue up 37% but going-concern doubt and lawsuits weigh

Securities class action lawsuits pile up Multiple law firms filed class actions alleging Nano-X overstated efficiency and demand, hid rising costs and cash burn, and misled investors. Legal costs, potential damages, and reputational damage weigh on the stock, though the suits are still pending.
This is a major new legal overhang that directly pressures NNOX shares.
Going-concern doubt after Q2 report Nano-X ended Q2 with $31.4 million cash, down from $60 million, and management warned of substantial doubt about continuing as a going concern. A $40.7 million impairment and $55.5 million net loss deepen fears of a cash crunch, pushing the stock down.
Going-concern doubt is a severe new risk that directly threatens the company's survival and stock price.
Revenue growth but slow commercialization Q2 revenue rose 37% to $4.2 million, with teleradiology up 14% and AI/software adding $1 million. The first Nanox Imaging Network site began collecting insurance payments, but management admitted commercialization is slower than expected, tempering the positive growth.
This shows the underlying business is growing but not fast enough to offset cash burn, a key tension for the stock.
Restructuring and manufacturing shift Nano-X is idling its South Korean chip fabrication, cutting that workforce by 67% and Israeli headcount by 15%, and shifting to third-party manufacturing. The plan saves only $2 million a year from 2027, raising doubts about its impact.
The restructuring is a direct response to the cash crisis and signals deeper operational problems.

Q2 202619 Jun – 26 Jun 2026

▼3▲1

Nanox Q1: Going-Concern Doubt, Guidance Withdrawn, Lawsuits Mount

Q1 2026: Going-concern doubt and guidance withdrawn Nanox reported Q1 revenue of $4.3 million but withdrew its 2026 revenue target and said it will no longer give annual guidance. It also disclosed $44.2 million in cash is not enough to fund the next 12 months, raising substantial doubt about its ability to continue as a going concern. This directly pressures the stock because it signals possible cash shortage and no clear revenue visibility.
This is the core new fundamental event that explains the period's negative move.
Securities class action lawsuits over alleged misleading statements Multiple law firms announced securities class actions alleging Nanox overstated efficiency gains and demand while hiding manufacturing problems. The lawsuits cover purchases from March 31, 2025 to April 17, 2026, with a lead plaintiff deadline of August 11, 2026. This adds legal costs and uncertainty, weighing on the stock.
New legal actions create fresh financial and reputational risk for NNOX.
South Korea operations may be sold or wound down Nanox is evaluating strategic alternatives for its South Korea operations, including a potential sale or wind-down. This follows a $17.5 million impairment and $18 million restructuring plan disclosed in April. A sale or shutdown could reduce future costs but also signals that part of the business is failing, hurting investor confidence.
This is a new strategic update that affects the company's cost structure and future prospects.
First commercial Nanox.ARC system in use at RadNet Nanox reported that a Nanox.ARC system is now in commercial use at a RadNet facility. This is a small but important milestone showing the product is finally being deployed in a real clinical setting. If it leads to more orders, it could support future revenue, but so far it is just one unit.
This is the only new positive operational development that could offset the negative financial news.

June 202619 Jun – 26 Jun 2026

▼3▲1

Nanox Q1: Going-Concern Doubt, Guidance Withdrawn, Lawsuits Mount

Q1 2026: Going-concern doubt and guidance withdrawn Nanox reported Q1 revenue of $4.3 million but withdrew its 2026 revenue target and said it will no longer give annual guidance. It also disclosed $44.2 million in cash is not enough to fund the next 12 months, raising substantial doubt about its ability to continue as a going concern. This directly pressures the stock because it signals possible cash shortage and no clear revenue visibility.
This is the core new fundamental event that explains the period's negative move.
Securities class action lawsuits over alleged misleading statements Multiple law firms announced securities class actions alleging Nanox overstated efficiency gains and demand while hiding manufacturing problems. The lawsuits cover purchases from March 31, 2025 to April 17, 2026, with a lead plaintiff deadline of August 11, 2026. This adds legal costs and uncertainty, weighing on the stock.
New legal actions create fresh financial and reputational risk for NNOX.
South Korea operations may be sold or wound down Nanox is evaluating strategic alternatives for its South Korea operations, including a potential sale or wind-down. This follows a $17.5 million impairment and $18 million restructuring plan disclosed in April. A sale or shutdown could reduce future costs but also signals that part of the business is failing, hurting investor confidence.
This is a new strategic update that affects the company's cost structure and future prospects.
First commercial Nanox.ARC system in use at RadNet Nanox reported that a Nanox.ARC system is now in commercial use at a RadNet facility. This is a small but important milestone showing the product is finally being deployed in a real clinical setting. If it leads to more orders, it could support future revenue, but so far it is just one unit.
This is the only new positive operational development that could offset the negative financial news.

19 Jun – 26 Jun 2026

▼3▲1

Nanox Q1: Going-Concern Doubt, Guidance Withdrawn, Lawsuits Mount

Q1 2026: Going-concern doubt and guidance withdrawn Nanox reported Q1 revenue of $4.3 million but withdrew its 2026 revenue target and said it will no longer give annual guidance. It also disclosed $44.2 million in cash is not enough to fund the next 12 months, raising substantial doubt about its ability to continue as a going concern. This directly pressures the stock because it signals possible cash shortage and no clear revenue visibility.
This is the core new fundamental event that explains the period's negative move.
Securities class action lawsuits over alleged misleading statements Multiple law firms announced securities class actions alleging Nanox overstated efficiency gains and demand while hiding manufacturing problems. The lawsuits cover purchases from March 31, 2025 to April 17, 2026, with a lead plaintiff deadline of August 11, 2026. This adds legal costs and uncertainty, weighing on the stock.
New legal actions create fresh financial and reputational risk for NNOX.
South Korea operations may be sold or wound down Nanox is evaluating strategic alternatives for its South Korea operations, including a potential sale or wind-down. This follows a $17.5 million impairment and $18 million restructuring plan disclosed in April. A sale or shutdown could reduce future costs but also signals that part of the business is failing, hurting investor confidence.
This is a new strategic update that affects the company's cost structure and future prospects.
First commercial Nanox.ARC system in use at RadNet Nanox reported that a Nanox.ARC system is now in commercial use at a RadNet facility. This is a small but important milestone showing the product is finally being deployed in a real clinical setting. If it leads to more orders, it could support future revenue, but so far it is just one unit.
This is the only new positive operational development that could offset the negative financial news.

Abbott Laboratories (ABT)

Q3 20265 Jul – 17 Sep 2026

▲3▼1

Abbott's Q3: strong sales, new products, but Exact Sciences deal weighs

Record Q2 sales and raised guidance Abbott reported record second-quarter sales of $12.6 billion, beat expectations, and raised its earnings guidance. Diagnostics grew 42.3% and Medical Devices grew 9%, showing broad strength across the business.
This is the core financial result that drove positive sentiment in the period.
New product approvals and partnerships FDA approved Freenome's colorectal cancer blood test, Abbott partnered with Google Health for Lingo, and won approvals for diabetes and heart devices like Libre Duo and Amulet 360. These expand future revenue streams.
These pipeline advances strengthen Abbott's long-term growth prospects.
Legal clouds ease with settlements Abbott partly settled NEC claims for $670 million and infant-formula claims for $385 million. This reduces legal uncertainty, though about 1,700 NEC lawsuits remain outstanding.
Legal settlements remove overhangs that had pressured the stock.
$21B Exact Sciences deal dilutes guidance Abbott's $21 billion acquisition of Exact Sciences diluted earnings guidance and increased interest expense. While it may boost long-term growth, the near-term financial impact weighed on the stock.
This is the main negative factor that offset positive developments.

September 202623 Aug – 17 Sep 2026

▲4

Abbott's legal clouds clear as new heart and diabetes devices win approvals

FDA clears first dual glucose-ketone sensor Abbott won FDA authorization for Libre Duo 10 Day, the first biowearable that tracks both glucose and ketones, with a U.S. launch planned for later this year. A genuinely new product with no direct rival strengthens Abbott's fast-growing diabetes sensor business and supports a higher stock price.
A first-of-its-kind product approval is a real new growth driver, not a repeat of earlier news.
Two new heart-device approvals widen Abbott's lead Abbott received CE Mark for the Amulet 360 stroke-prevention device and FDA approval for the TactiFlex Duo ablation catheter, its fourth and fifth heart-rhythm approvals in about a year. More approved tools mean more procedures and recurring sales, pushing the stock up.
These are new regulatory wins that expand Abbott's electrophysiology lineup and revenue runway.
Infant formula legal overhang largely resolved Abbott agreed to pay $385 million to settle Department of Justice and state claims over its 2022 Sturgis formula recall, with no finding of fault and the criminal probe closed. Removing this legal cloud lets investors focus on the core business, lifting the stock.
This is a new settlement that clears a major legal risk, a direct positive for the share price.
Citi sees Abbott taking heart-device share from Boston Scientific Citi downgraded rival Boston Scientific, saying it will lose market share in left atrial appendage closure when Abbott's Amulet device launches in 2027. That independent view of Abbott as the winner in a growing market supports the stock.
A fresh analyst call frames Abbott as a competitive gainer, a new reason for optimism.

Latest23 Aug – 17 Sep 2026

▲4

Abbott's legal clouds clear as new heart and diabetes devices win approvals

FDA clears first dual glucose-ketone sensor Abbott won FDA authorization for Libre Duo 10 Day, the first biowearable that tracks both glucose and ketones, with a U.S. launch planned for later this year. A genuinely new product with no direct rival strengthens Abbott's fast-growing diabetes sensor business and supports a higher stock price.
A first-of-its-kind product approval is a real new growth driver, not a repeat of earlier news.
Two new heart-device approvals widen Abbott's lead Abbott received CE Mark for the Amulet 360 stroke-prevention device and FDA approval for the TactiFlex Duo ablation catheter, its fourth and fifth heart-rhythm approvals in about a year. More approved tools mean more procedures and recurring sales, pushing the stock up.
These are new regulatory wins that expand Abbott's electrophysiology lineup and revenue runway.
Infant formula legal overhang largely resolved Abbott agreed to pay $385 million to settle Department of Justice and state claims over its 2022 Sturgis formula recall, with no finding of fault and the criminal probe closed. Removing this legal cloud lets investors focus on the core business, lifting the stock.
This is a new settlement that clears a major legal risk, a direct positive for the share price.
Citi sees Abbott taking heart-device share from Boston Scientific Citi downgraded rival Boston Scientific, saying it will lose market share in left atrial appendage closure when Abbott's Amulet device launches in 2027. That independent view of Abbott as the winner in a growing market supports the stock.
A fresh analyst call frames Abbott as a competitive gainer, a new reason for optimism.

August 20264 Aug – 20 Aug 2026

▲3▼1

Abbott's core growth accelerates as Google deal and NEC settlement reshape outlook

Google Health partnership expands Lingo reach Abbott and Google launched a multi-year partnership to embed Lingo glucose data into the Google Health app, pairing it with AI coaching. This could drive adoption of Abbott's biowearable and open a new consumer health channel, supporting the stock.
New partnership is a fresh growth catalyst for Abbott's diabetes care business.
Instinct sensor powers MiniMed's new insulin pump Abbott is supplying its Instinct sensor for MiniMed's app-controlled insulin pump in the U.S. This broadens Abbott's role in diabetes devices and adds recurring sensor revenue, a positive for the stock.
New product integration expands Abbott's diabetes device footprint.
Medical devices growth driven by electrophysiology and CGM Abbott's medical devices arm is accelerating, with the Volt PFA catheter launching fully and CGM adoption far below its 75-80 million potential users. This long runway supports future revenue growth and a higher stock price.
Highlights durable growth drivers in Abbott's largest device segments.
NEC litigation settled for $670 million, but 1,700 cases remain Abbott agreed to pay about $670 million to settle the Gill case and roughly 2,000 NEC claims, without admitting liability. While this removes a major overhang, about 1,700 lawsuits remain, keeping some legal uncertainty on the stock.
Settlement is a major legal development that reduces but does not eliminate litigation risk.

4 Aug – 20 Aug 2026

▲3▼1

Abbott's core growth accelerates as Google deal and NEC settlement reshape outlook

Google Health partnership expands Lingo reach Abbott and Google launched a multi-year partnership to embed Lingo glucose data into the Google Health app, pairing it with AI coaching. This could drive adoption of Abbott's biowearable and open a new consumer health channel, supporting the stock.
New partnership is a fresh growth catalyst for Abbott's diabetes care business.
Instinct sensor powers MiniMed's new insulin pump Abbott is supplying its Instinct sensor for MiniMed's app-controlled insulin pump in the U.S. This broadens Abbott's role in diabetes devices and adds recurring sensor revenue, a positive for the stock.
New product integration expands Abbott's diabetes device footprint.
Medical devices growth driven by electrophysiology and CGM Abbott's medical devices arm is accelerating, with the Volt PFA catheter launching fully and CGM adoption far below its 75-80 million potential users. This long runway supports future revenue growth and a higher stock price.
Highlights durable growth drivers in Abbott's largest device segments.
NEC litigation settled for $670 million, but 1,700 cases remain Abbott agreed to pay about $670 million to settle the Gill case and roughly 2,000 NEC claims, without admitting liability. While this removes a major overhang, about 1,700 lawsuits remain, keeping some legal uncertainty on the stock.
Settlement is a major legal development that reduces but does not eliminate litigation risk.

July 20265 Jul – 28 Jul 2026

▲3▼1

Abbott beats Q2, raises guidance, but Exact Sciences costs and NEC litigation weigh

Q2 earnings beat and raised guidance Abbott reported record Q2 sales of $12.6 billion, up 13%, and adjusted EPS of $1.31, beating expectations. Management raised full-year EPS guidance to $5.45–$5.60, sending the stock up over 10% initially.
This is the main new event that drove the stock in July.
Medical Devices and Diagnostics growth Medical Devices grew 9%, while Diagnostics surged 42.3% due to the Exact Sciences acquisition. Nutrition trends also improved, showing broad-based strength across Abbott's businesses.
These segment results explain the strong revenue beat and support the positive reaction.
FDA approval of Freenome CRC blood test The FDA approved Freenome's colorectal cancer blood test, which Abbott will exclusively commercialize in the U.S. This adds a new revenue stream and expands Abbott's diagnostic offerings.
This is a new product approval that could drive future growth.
Exact Sciences costs and NEC litigation The $21 billion Exact Sciences deal diluted guidance and spiked interest expense from $50 million to $299 million. Ongoing NEC litigation uncertainty continues to weigh on investor sentiment, keeping a lid on the stock.
These are the main counterweights that prevented even stronger gains.

21 Jul – 28 Jul 2026

▲2▼2

Abbott's Q2 beat and raised guidance offset by Exact Sciences dilution and NEC litigation

Q2 beat and raised guidance Abbott reported record Q2 sales of $12.6 billion, up 13%, and adjusted EPS of $1.31, beating estimates. Management raised full-year adjusted EPS guidance to $5.45–$5.60. This shows the core business is strong and supports a higher stock price.
This is the main positive driver this period, directly boosting investor confidence and the stock's valuation.
FDA approves Freenome CRC blood test, Abbott to commercialize The FDA approved Freenome's SimpleScreen CRC blood test, and Abbott will exclusively sell it in the U.S. starting this fall. This expands Abbott's cancer diagnostics portfolio and adds a new revenue stream, pushing the stock up.
This is a new product approval that directly expands Abbott's diagnostics business and future sales.
Exact Sciences acquisition dilutes guidance and raises interest expense Abbott's $21 billion Exact Sciences acquisition added $919 million in Cologuard sales but also caused interest expense to jump from $50 million to $299 million and diluted full-year guidance. This weighs on the stock as investors worry about the cost of the deal.
This is a key counterweight explaining why the stock hasn't risen more despite strong results.
Ongoing NEC litigation uncertainty Uncertainty around NEC litigation related to Abbott's preterm infant formula continues to weigh on investor sentiment. This legal risk keeps a lid on the stock price, as investors await clarity on potential liabilities.
This is a persistent negative factor that offsets positive business momentum.

5 Jul – 17 Jul 2026

▲3

Abbott beats Q2, raises guidance, stock jumps 11%

Q2 beat and raised full-year guidance Abbott reported Q2 adjusted EPS of $1.31, beating estimates, with sales up 13% to $12.59 billion. Management raised full-year adjusted EPS guidance to $5.45–$5.60 and reaffirmed comparable sales growth of 6.5–7.5%. The stock jumped over 10% as results eased worries about medical devices and nutrition.
This is the main new event that directly drove the stock's sharp move this period.
Medical Devices and Diagnostics strength Medical Devices sales grew 9% to $5.85 billion, led by electrophysiology and diabetes care. Diagnostics surged 42.3% to $3.09 billion after the Exact Sciences acquisition, with cancer diagnostics growing double digits. This shows the core businesses are performing well and supports future growth.
It explains which parts of the business are driving the beat and future optimism.
Nutrition and other segments improving Nutrition sales declined 3.1% but rose sequentially by $125 million, and management expects about 80% of the second-half lift from Nutrition, Electrophysiology, Core Laboratory, and Cancer Diagnostics. Established Pharmaceuticals grew 8.4%. This signals a turnaround in previously weak areas.
It shows the company is addressing prior weaknesses, which supports the raised guidance.

Q2 202620 Jun – 1 Jul 2026

▲4

Abbott's legal cloud lifts, dividend grows, and new products drive optimism

DOJ ends criminal probe into baby formula plant The U.S. Justice Department closed its criminal investigation into Abbott's Michigan baby formula plant, opting for civil penalties instead. This removes a major legal risk that had been hanging over the company, making the stock more attractive to investors.
This is a new development that directly reduces regulatory uncertainty and boosts investor confidence.
Abbott raises dividend for 54th straight year Abbott increased its dividend for the 54th consecutive year, with a quarterly payout of $0.740243 per share, yielding 2.76%. This signals financial strength and a commitment to returning cash to shareholders, which can support the stock price.
This is a new event that highlights Abbott's financial health and shareholder returns.
New Alzheimer's blood test licensing deal ALZpath licensed its pTau217 antibody to Abbott for a blood-based Alzheimer's test on Abbott's Alinity systems. This expands Abbott's diagnostic portfolio into a large, growing market, potentially adding new revenue streams.
This is a new partnership that opens a new market opportunity for Abbott.
FreeStyle Libre expansion into Type 2 basal insulin market Abbott's FreeStyle Libre continuous glucose monitor is expanding into the large Type 2 basal-insulin market, with trial data showing improved outcomes. This could significantly increase the addressable market and drive future sales growth.
This is a new catalyst that could accelerate growth in Abbott's diabetes care business.

June 202620 Jun – 1 Jul 2026

▲4

Abbott's legal cloud lifts, dividend grows, and new products drive optimism

DOJ ends criminal probe into baby formula plant The U.S. Justice Department closed its criminal investigation into Abbott's Michigan baby formula plant, opting for civil penalties instead. This removes a major legal risk that had been hanging over the company, making the stock more attractive to investors.
This is a new development that directly reduces regulatory uncertainty and boosts investor confidence.
Abbott raises dividend for 54th straight year Abbott increased its dividend for the 54th consecutive year, with a quarterly payout of $0.740243 per share, yielding 2.76%. This signals financial strength and a commitment to returning cash to shareholders, which can support the stock price.
This is a new event that highlights Abbott's financial health and shareholder returns.
New Alzheimer's blood test licensing deal ALZpath licensed its pTau217 antibody to Abbott for a blood-based Alzheimer's test on Abbott's Alinity systems. This expands Abbott's diagnostic portfolio into a large, growing market, potentially adding new revenue streams.
This is a new partnership that opens a new market opportunity for Abbott.
FreeStyle Libre expansion into Type 2 basal insulin market Abbott's FreeStyle Libre continuous glucose monitor is expanding into the large Type 2 basal-insulin market, with trial data showing improved outcomes. This could significantly increase the addressable market and drive future sales growth.
This is a new catalyst that could accelerate growth in Abbott's diabetes care business.

20 Jun – 1 Jul 2026

▲4

Abbott's legal cloud lifts, dividend grows, and new products drive optimism

DOJ ends criminal probe into baby formula plant The U.S. Justice Department closed its criminal investigation into Abbott's Michigan baby formula plant, opting for civil penalties instead. This removes a major legal risk that had been hanging over the company, making the stock more attractive to investors.
This is a new development that directly reduces regulatory uncertainty and boosts investor confidence.
Abbott raises dividend for 54th straight year Abbott increased its dividend for the 54th consecutive year, with a quarterly payout of $0.740243 per share, yielding 2.76%. This signals financial strength and a commitment to returning cash to shareholders, which can support the stock price.
This is a new event that highlights Abbott's financial health and shareholder returns.
New Alzheimer's blood test licensing deal ALZpath licensed its pTau217 antibody to Abbott for a blood-based Alzheimer's test on Abbott's Alinity systems. This expands Abbott's diagnostic portfolio into a large, growing market, potentially adding new revenue streams.
This is a new partnership that opens a new market opportunity for Abbott.
FreeStyle Libre expansion into Type 2 basal insulin market Abbott's FreeStyle Libre continuous glucose monitor is expanding into the large Type 2 basal-insulin market, with trial data showing improved outcomes. This could significantly increase the addressable market and drive future sales growth.
This is a new catalyst that could accelerate growth in Abbott's diabetes care business.